Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
56 results about "Targeted immunotherapy" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Broadly speaking, immunotherapy is the use of immune cells from the patients or a donor to elicit an anti-cancer effect. Targeted therapy, is a therapy that aims to specifically target cancer cells, while sparing healthy cells.
Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs
InactiveUS20030138432A1Improve targeting selectivityHigh affinityNanomedicineAntibody ingredientsDelivery vehicleTherapeutic intent
The present invention relates to the compositions, methods, and applications of a novel approach to selective cellular targeting. The purpose of this invention is to enable the selective delivery and / or selective activation of effector molecules to target cells for diagnostic or therapeutic purposes. The present invention relates to multi-functional prodrugs or targeting vehicles wherein each functionality is capable of enhancing targeting selectivity, affinity, intracellular transport, activation or detoxification. The present invention also relates to ultra-low dose, multiple target, multiple drug chemotherapy and targeted immunotherapy for cancer treatment.
Owner:DRUG INNOVATION & DESIGN
Human Anti-Tau Antibodies
Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.
Owner:UNIV ZURICH +1
Compounds for targeted immunotherapy
Compounds for targeted immunotherapy, compositions comprising the compounds and use of the compounds in the treatment of diseases such as cancer are disclosed. The compounds having the structure of formula TM-Ln-AM, wherein TM is a targeting moiety, AM is an activating moiety that is capable of activating a human dendritic cell, NK cell, or tumor cell, or a combination thereof, Ln is a linker, and n is an integer selected from 0 and 1.
Owner:BIRDIE BIOPHARM INC
Method for enhancing specific immunotherapies in cancer treatment
ActiveUS20140086932A1Enhance immune functionGood curative effectSnake antigen ingredientsPharmaceutical delivery mechanismCompound (substance)Targeted immunotherapy
Methods and compositions of the invention relate to the enhancement of specific immunotherapies in cancer treatment. In particular, aspects of the invention relate to novel approaches to boost immune function using a complex carbohydrate pharmaceutical compound alone or in combination with other targeted immunotherapy to increase the efficacy of immunotherapy of cancer.
Owner:PROVIDENCE HEALTH & SERVICES OREGON D B A EARLE A CHILES RES INST OF THE ROBERT W FRANZ CANCER RES CENT AT PROVIDENCE PORTLAND MEDICAL CENT +1
Human Anti-tau antibodies
InactiveUS20130295021A1Reduce riskSlow onsetBacteriaPeptide/protein ingredientsTargeted immunotherapySpecific antibody
Provided are human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.
Owner:BIOGEN INT NEUROSCI +1
Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
InactiveUS20050137384A1Extended half-lifeAltering pharmacology and biodistributionPeptide/protein ingredientsAntibody mimetics/scaffoldsWhite blood cellStepwise approach
Disclosed are methods for producing fusion proteins with the heterodimeric cytokine, interleukin-12. In order to insure that the proper ratio of fused and non-fused subunits are obtained in the fusion protein, a specific stepwise approach to genetic engineering is used. This consists of first expressing the non-fused p40 IL-12 subunit in a production cell line, followed by or simultaneously expressing in the same cell, a second recombinant fusion protein consisting of the fused polypeptide linked by a peptide bond to the p35 subunit of IL-12. Molecules containing the p35 fusion protein cannot be secreted from the transfected mammalian cell without first complexing in a one to one ratio with the p40 subunit, thus ensuring the production of active heterodimeric fusion proteins.
Owner:MERCK PATENT GMBH
Human anti-tau antibodies
ActiveUS8940272B2Reduce riskSlow onsetBacteriaLibrary screeningTargeted immunotherapySpecific antibody
Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.
Owner:UNIV ZURICH +1
Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
InactiveUS7226998B2Altering pharmacology and biodistributionIncreasing its circulating half-life and its affinityPeptide/protein ingredientsAntibody mimetics/scaffoldsStepwise approachImmune therapy
Disclosed are methods for producing fusion proteins with the heterodimeric cytokine, interleukin-12. In order to insure that the proper ratio of fused and non-fused subunits are obtained in the fusion protein, a specific stepwise approach to genetic engineering is used. This consists of first expressing the non-fused p40 IL-12 subunit in a production cell line, followed by or simultaneously expressing in the same cell, a second recombinant fusion protein consisting of the fused polypeptide linked by a peptide bond to the p35 subunit of IL-12. Molecules containing the p35 fusion protein cannot be secreted from the transfected mammalian cell without first complexing in a one to one ratio with the p40 subunit, thus ensuring the production of active heterodimeric fusion proteins.
Owner:MERCK PATENT GMBH
Compounds and Compositions for Treating EGFR Expressing Tumors
Provided are compounds for targeted immunotherapy. The compounds are useful in the treatment of EGFR expressing tumors / cancers. Also provided are compositions comprising the compounds.
Owner:BIRDIE BIOPHARM INC
Compounds for targeted immunotherapy
Compounds for targeted immunotherapy, compositions comprising the compounds and use of the compounds in the treatment of diseases such as cancer are disclosed. The compounds having the structure of formula TM-Ln-AM, wherein TM is a targeting moiety, AM is an activating moiety that is capable of activating a human dendritic cell, NK cell, or tumor cell, or a combination thereof, Ln is a linker, and n is an integer selected from 0 and 1.
Owner:BIRDIE BIOPHARM INC
Compounds for targeted immunotherapy
ActiveUS20180177888A1Organic active ingredientsPharmaceutical non-active ingredientsDiseaseDendritic cell
Compounds for targeted immunotherapy, compositions comprising the compounds and use of the compounds in the treatment of diseases such as cancer are disclosed. The compounds having the structure of formula TM-Ln-AM, wherein TM is a targeting moiety, AM is an activating moiety that is capable of activating a human dendritic cell, NK cell, or tumor cell, or a combination thereof, Ln is a linker, and n is an integer selected from 0 and 1.
Owner:BIRDIE BIOPHARM INC
Human anti-alpha-synuclein antibodies
Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for α-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for α-synuclein targeted immunotherapy and diagnosis, respectively.
Owner:BIOGEN INT NEUROSCI +1
Methods and compositions for pharmacologially controlled targeted immunotherapy
InactiveUS20070134259A1Promotes complement-mediated cytotoxicityOrganic active ingredientsBiocideMolecular Targeted TherapiesTargeted immunotherapy
The present invention relates generally to methods and compositions for targeted immunotherapy. More specifically, the present invention relates to immuno-targeted therapies, using heteromultivalent compounds to mediate the binding of an endogenous effector molecule such as an antibody to target molecules including malignant cells and tissues, bacteria and viruses as well as their toxic agents.
Owner:THE GOVERNORS OF THE UNIV OF ALBERTA
Human Anti-Alpha-Synuclein Antibodies
Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for α-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for α-synuclein targeted immunotherapy and diagnosis, respectively.
Owner:BIOGEN INT NEUROSCI +1
Novel Anti-fibroblast activation protein (FAP) binding agents and uses thereof
InactiveUS20180022822A1Enhance tumor targeting tumorEnhance tumor tumor selectivityAntibody mimetics/scaffoldsAntipyreticAntigenAntigen receptors
Provided are novel human-derived antibodies specific for Fibroblast Activation Protein (FAP), preferably capable of selectively inhibiting the enzymatic activity of FAP, and chimeric antigen receptors (CARs) directed against the human FAP antigen as well as methods related thereto. In addition, methods of diagnosing and / or monitoring diseases and treatments thereof which are associated with FAP are provided. Assays and kits related to antibodies specific for FAP are also disclosed. The novel anti-FAP antibodies can be used in pharmaceutical and diagnostic compositions for FAP-targeted immunotherapy and diagnostics.
Owner:MABIMMUNE DIAGNOSTICS AG
Human Anti-tau antibodies
ActiveUS20150344553A1Reduce riskSlow onsetNervous disorderBacteriaTargeted immunotherapySpecific antibody
Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.
Owner:BIOGEN MA INC +1
Human anti-tau antibodies
ActiveUS9598484B2Reduce riskSlow onsetNervous disorderImmunoglobulins against animals/humansTargeted immunotherapySpecific antibody
Provided are human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.
Owner:BIOGEN MA INC +1
Anti-α synuclein binding molecules
ActiveUS9580493B2Reduce riskPreventing a clinically manifest synucleinopathic diseaseNervous disorderImmunoglobulins against animals/humansEpitopeAntigen Binding Fragment
Provided are anti-human α-synuclein-specific binding molecules, e.g., antibodies or antigen-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human α-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human α-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for α-synuclein targeted immunotherapy and diagnosis, respectively.
Owner:BIOGEN INT NEUROSCI +1
Compound for immunotherapy, and composition
InactiveCN104861067AImmunoglobulinsPharmaceutical non-active ingredientsDiseaseTargeted immunotherapy
The present invention relates to a compound for targeting immunotherapy, and a composition containing the compound. The present invention further relates to applications of the compound in treatment of diseases such as cancers.
Owner:BIRDIE BIOPHARM INC
Antibody-based therapy of transthyretin (TTR) amyloidosis and human-derived antibodies therefor
Provided are novel human-derived antibodies specific for transthyretin (TTR), preferably capable of binding misfolded, misassembled, and / or aggregated TTR species, as well as methods related thereto. In addition, methods of diagnosing and / or monitoring diseases and treatments thereof which are associated with TTR amyloidosis are provided. Assays and kits related to anti-bodies specific for TTR or TTR deposits and aggregates are also disclosed. The novel anti-TTR antibodies can be used in pharmaceutical and diagnostic compositions for TTR targeted immunotherapy and diagnostics.
Owner:NEURIMMUNE HLDG
Human anti-SOD1 antibodies
ActiveCN103380145AMonitor disease progressionMonitor therapeuticMuscular disorderVertebrate antigen ingredientsDismutaseSuperoxide dismutases
Provided are novel human copper-zinc superoxide dismutase, also known as superoxide dismutase 1 or SOD1, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for SOD1 are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for SOD1 targeted immunotherapy and diagnosis, respectively.
Owner:NEURIMMUNE HLDG +1
Method for enhancing specific immunotherapies in cancer treatment
ActiveUS9872909B2Good curative effectEnhance immune functionPharmaceutical delivery mechanismImmunoglobulins against cell receptors/antigens/surface-determinantsCancer therapyTargeted immunotherapy
Methods and compositions of the invention relate to the enhancement of specific immunotherapies in cancer treatment. In particular, aspects of the invention relate to novel approaches to boost immune function using a complex carbohydrate pharmaceutical compound alone or in combination with other targeted immunotherapy to increase the efficacy of immunotherapy of cancer.
Owner:PROVIDENCE HEALTH & SERVICES OREGON D B A EARLE A CHILES RES INST OF THE ROBERT W FRANZ CANCER RES CENT AT PROVIDENCE PORTLAND MEDICAL CENT +1
Circulating tumor cell diagnostics for therapy targeting pd-l1
Owner:EPIC SCIENCES
Tdp-43 specific binding molecules
Provided are novel TDP-43-specific binding molecules including polypeptides such as human antibodies, as well as fragments, derivatives and variants thereof. Also provided are methods related to these TDP-43 specific binding molecules. Assays, kits, and solid supports related to TDP-43-specific binding molecules, including polypeptides such as, human antibodies are also disclosed. The TDP-43-specific binding molecule, antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for TDP-43 targeted immunotherapy and diagnosis, respectively.
Owner:UNIV ZURICH +1
Anti-Alpha Synuclein Binding Molecules
ActiveUS20140369940A1Inhibit bindingReduce riskNervous disorderBacteriaEpitopeAntigen Binding Fragment
Provided are anti-human α-synuclein-specific binding molecules, e.g., antibodies or antigen-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human α-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human α-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for α-synuclein targeted immunotherapy and diagnosis, respectively.
Owner:BIOGEN INT NEUROSCI +1
Anti PD-L1 conjugates for treating tumors
ActiveUS11130812B2Organic active ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsAntiendomysial antibodiesAntibody conjugate
The present invention discloses anti-PD-L / PD-1 Axis antibody conjugates for targeted immunotherapy, as well as compositions comprising said conjugates. Further, the present invention discloses the use of the conjugates in the treatment of tumor / cancer.
Owner:BIRDIE BIOPHARM INC
HER2 positive tumor targeting compound and composition thereof
InactiveCN104861063AImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsTumor targetingTargeted immunotherapy
The present invention provides a HER2 positive tumor targeting compound and a composition thereof, and relates to a compound used for the targeting immunotherapy method, and a composition containing the compound. The present invention further relates to applications of the compound in treatment of HER2-positive tumors / cancers.
Owner:BIRDIE BIOPHARM INC
Human-derived Anti-dipeptide repeats (DPRS) antibody
Provided are novel human-derived dipeptide repeat (DPR) specific antibodies as well as synthetic variants and biotechnological derivatives thereof, preferably capable of binding C9ORF72 DPRs, as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for DPRs and DPR proteins such C9ORF72 DPRs are also disclosed. The antibody of the present invention can be used in pharmaceutical and diagnostic compositions for DPR protein-targeted immunotherapy and diagnostics.
Owner:NEURIMMUNE HLDG
Autoimmune encephalitis antibody transient transfection and stable transfection detection method and application thereof
PendingCN113755443ABiological material analysisMicroorganism based processesImmunofluorescenceTransient transfection
The invention provides an autoimmune encephalitis antibody transient transfection and stable transfection detection method and application thereof. Specifically, the invention provides a recombinant cell for expressing mutant NMDAR, the recombinant cell expresses fusion protein of exogenous mutant NMDAR and fluorescent protein, and the transfection survival rate is high. The recombinant cell provided by the invention can be used for detecting antibodies related to autoimmune encephalitis, including NMDAR, AMPAR1, AMPAR2, LGI1, Caspr2 and GABABR. The invention also provides a method for detecting anti-autoimmune encephalitis by using the transfected cell line through an indirect immunofluorescence method based on the recombinant transfected cell line provided by the invention. The method disclosed by the invention has high sensitivity and specificity, and can be used for accurately detecting the types of pathogenic antibodies so as to help a patient to carry out targeted immunotherapy and recover health.
Owner:陈向军
Conjugate of influenza A virus conservative peptides M2e and virus-like particles, and application thereof
InactiveCN103083656AShort preparation timeEase of mass productionAntiviralsCarrier-bound antigen/hapten ingredientsHuman influenzaVirus-like particle
The invention relates to a conjugate of virus-like particles (VLP) of oligopeptide vector Q[beta] bacteriophage with target immunotherapy and conservative peptides M2e of human influenza virus M2 protein. The conjugate is mainly used for preventing human influenza A. The conjugate is coupled by a Sulfo-SMCC method which comprises a first step of preparing the virus-like particles (VLP) of the Q[beta] bacteriophage; a second step of preparing the virus-like particles (VLP) activated by Sulfo-SMCC; and a third step of preparing the conjugate of M2e-VLP. The conjugate can produce high titer protective antibody in mice and cross-protect the attack of various subtypes of the influenza A viruses.
Owner:苏州科贝生物技术有限公司
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com